Healthcare Industry News: Bard
News Release - June 29, 2011
Bovine Carotid Artery (BCA) For Hemodialysis Access: 3-Year Prospective, Randomized Clinical Study at Massachusetts General Hospital Confirms Superiority of Artegraft to Cuffed ePTFENorth Brunswick, NJ-- The Journal of Vascular Surgery, in its June 2011 issue, has published the clinical results of a three-year prospective, randomized study comparing Artegraft(R) (Bovine Carotid Artery) to Bard Venaflo(R) for hemodialysis access. The study's conclusion: The BCA graft is an excellent option for patients on hemodialysis who are not eligible for native arteriovenous fistulas, as these grafts required fewer interventions than the ePTFE grafts to maintain patency.
Artegraft vs Venaflo
Overall Primary Patency Rate at 1 Year 60% vs 10%
Assisted Primary Patency Rate at 1 Year 60% vs 20%
Assisted Primary Patency Rate at 2 Years 40% vs 14%
Less Thrombosis and Fewer Interventions with BCA
No Pseudoaneurysms with BCA
President & CEO
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.